Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Viral Hepatitis Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection

NCT01768286
View directory record Official record
Conditions
Chronic Hepatitis C Virus
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
53
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers

NCT02404805
View directory record Official record
Conditions
HIV, Hepatitis C
Interventions
dolutegravir, simeprevir
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Phase 4 Interventional Results available

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.

NCT00087594
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
peginterferon alfa-2a [Pegasys], ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
7
States / cities
San Francisco, California • Farmington, Connecticut • Honolulu, Hawaii + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers

NCT00895102
View directory record Official record
Conditions
HCV Infection
Interventions
ABT-333 Tablet, Placebo, ABT-333 Capsule
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 12, 2010 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Phase 2 Interventional Results available

The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients

NCT03819322
View directory record Official record
Conditions
Liver Transplant, Hepatitis C
Interventions
sofosbuvir/velpatasvir
Drug
Lead sponsor
Fernanda P Silveira, MD, MS
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function

NCT02296905
View directory record Official record
Conditions
Hepatic Impairment
Interventions
ABT-493, ABT-530
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Phase 2 Interventional

Ph IIA Study (SOC +/- NS5B)

NCT01193361
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
BMS-791325, Placebo, Peg-interferon alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Anaheim, California • Maywood, Illinois • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Jul 22, 2026, 12:56 AM EDT
Completed No phase listed Observational

Association Between Hepatitis C Infection and Renal Cell Carcinoma

NCT01405183
View directory record Official record
Conditions
Hepatitis C, Renal Cell Carcinoma, Colorectal Cancer
Interventions
Hepatitis C testing
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of Hepatitis E Vaccine (HEV239)

NCT03827395
View directory record Official record
Conditions
Hepatitis E, Immunisation
Interventions
HEV 239, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

NCT02707601
View directory record Official record
Conditions
HIV-1 Infection, HCV Infection
Interventions
E/C/F/TAF, F/R/TAF, LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Phase 3 Interventional

UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects

NCT01979939
View directory record Official record
Conditions
Hepatitis C
Interventions
DCV/ASV/BMS-791325
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
42
States / cities
La Jolla, California • San Diego, California • San Francisco, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Phase 2 Interventional

Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed

NCT00968357
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
SCV-07
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Anaheim, California • Los Angeles, California • Palm Springs, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Phase 4 Interventional Results available

Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication

NCT03823911
View directory record Official record
Conditions
Cardiovascular Diseases, Hepatitis C, Hiv
Interventions
Elbasvir / Grazoprevir Oral Tablet [Zepatier], Cardiac MRI
Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Phase 2 Interventional Results available

Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus

NCT01628692
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Daclatasvir, Simeprevir, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
San Francisco, California • Indianapolis, Indiana • Lutherville, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Jul 22, 2026, 12:56 AM EDT
Completed No phase listed Observational Results available

Hepatitis C Virus (HCV) Treatment Completion or Withdrawal

NCT00674492
View directory record Official record
Conditions
Hepatitis C
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Jul 22, 2026, 12:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hepatitis C Infection in World Trade Center Responders

NCT02982993
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
51 Years to 72 Years
Enrollment
3,906 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2019 · Synced Jul 22, 2026, 12:56 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Assessing Performance of a Hepatitis C Emergency Department (HepC-EnD) Screening Tool: IT Integration Process for Electronic Health Record System

NCT07406490
View directory record Official record
Conditions
Hepatitis C Virus (HCV), Hepatitis C Virus (HCV) Infection, HIV (Human Immunodeficiency Virus)
Interventions
Physician-Initiated Screening (Conventional Screening), FOCUS (Universal Screening), HepC-EnD (Targeted Screening)
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 79 Years
Enrollment
6,466 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Not applicable Interventional Results available

A Randomized Trial of Vaccine Adherence in Young Injection Drug Users

NCT00244374
View directory record Official record
Conditions
Medication Adherence, Substance Abuse, Intravenous, Risk Behavior, Hepatitis A, Hepatitis B, Hepatitis C
Interventions
Hepatitis A & B vaccine, Outreach, AIC, SEP
Biological · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
14 Years to 29 Years
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2013 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325

NCT02095860
View directory record Official record
Conditions
Hepatitis C
Interventions
DCV 3DAA FDC
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 49 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Jul 22, 2026, 12:56 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype

NCT01459913
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Telaprevir, Pegylated Interferon Alfa-2a, Ribavirin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Health Problems Associated With Injection Drug Use

NCT01128920
View directory record Official record
Conditions
Intravenous Drug Abuse, HIV Infections
Interventions
Skin and Needle Hygiene Intervention, No intervention - assessment-only condition
Behavioral · Other
Lead sponsor
University of Northern Colorado
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 3, 2012 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Not applicable Interventional Results available

Web-based Intervention to Reduce Alcohol Use in Veterans With Hepatitis C

NCT01707030
View directory record Official record
Conditions
Hepatitis C, Alcohol Abuse
Interventions
Web-Based Brief Alcohol Intervention, Usual Care
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Palo Alto, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.

NCT01277692
View directory record Official record
Conditions
Hepatitis C
Interventions
GSK2336805 10mg, GSK2336805 30mg, GSK2236805 100mg, GSK2236805 200mg, GSK2236805 10mg, GSK2236805 dose to be determined up to 100mg, GSK2236805 5mg, GSK2236805 30mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
Chula Vista, California • Lenexa, Kansas • Willingboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects

NCT00983957
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
BMS-790052, Ortho Tri-Cyclen®
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Tempe, Arizona • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Jul 22, 2026, 12:56 AM EDT